{"id":30200,"date":"2024-03-14T14:23:00","date_gmt":"2024-03-14T04:23:00","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30200"},"modified":"2025-01-14T10:31:28","modified_gmt":"2025-01-14T00:31:28","slug":"prescient-therapeutics-research-briefing","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/","title":{"rendered":"Prescient Therapeutics Research Briefing"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm61d1458 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm5a8d886\" class=\"wp-block-gutentor-m4 section-gm5a8d886 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm265cc5\" class=\"wp-block-gutentor-m4-col col-gm265cc5 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm265cc5\" class=\"section-gm265cc5 gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX)<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gme8d3fca\" class=\"wp-block-gutentor-m4 section-gme8d3fca gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm4f3558\" class=\"wp-block-gutentor-m4-col col-gm4f3558 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gm4f3558\" class=\"section-gm4f3558 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\" alt=\"\" class=\"wp-image-30217\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/923187777?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmfc9988\" class=\"wp-block-gutentor-m4-col col-gmfc9988 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gmfc9988\" class=\"section-gmfc9988 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Reach Markets interviewed Co-Founder and Senior Analyst of Pitt Street Research, Stuart Roberts, who released a research report on PTX which discusses Prescient&#8217;s flagship asset &#8211; PTX-100 &#8211; and how they are addressing a disease with a significantly unmet need.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">During this session, Stuart discusses:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>The report which highlights the encouraging preliminary Phase 1b data and the considerable market opportunity for a new and effective drug in TCL, which is a disease that is underserved by existing therapies.<\/li>\n\n\n\n<li>Their valuation of PTX as outlined in last November\u2019s initiation report, at 11.6c per share base case and 16.3c per share in an optimistic (or bull) case.<\/li>\n\n\n\n<li>While only around 5,000-6,000 people a year will be diagnosed with a T-Cell Lymphoma in the US alone, the market opportunity could be in the billions, citing Acrotech Biopharma&#8217;s Folotyn with its $842,585 per patient per year price tag as a guide.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 14th March 2024 (AEDT)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gmb374e1d gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gm80836ae\" class=\"wp-block-gutentor-m4 section-gm80836ae gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gma9fff1\" class=\"wp-block-gutentor-m4-col col-gma9fff1 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gma9fff1\" class=\"section-gma9fff1 gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm9a71a1\" class=\"wp-block-gutentor-m4-col col-gm9a71a1 gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gm9a71a1\" class=\"section-gm9a71a1 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"225\" height=\"225\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-2-Prescient-Therapeutics-Research-Briefing-BIO-PHOTO.jpeg\" alt=\"\" class=\"wp-image-30202\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-2-Prescient-Therapeutics-Research-Briefing-BIO-PHOTO.jpeg 225w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-2-Prescient-Therapeutics-Research-Briefing-BIO-PHOTO-150x150.jpeg 150w\" sizes=\"auto, (max-width: 225px) 100vw, 225px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">Stuart Roberts<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">Co-Founder and Senior Analyst at Pitt Street Research<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Stuart covered healthcare and biotechnology for the stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015 where he developed a reputation for detailed analysis on previously uncovered Life Science companies. After 15 months working for two ASX-listed drug development companies in 2015 and early 2016 he returned to equities research, co-founding Pitt Street Research.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm954aa3\" class=\"wp-block-gutentor-m4-col col-gm954aa3 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm954aa3\" class=\"section-gm954aa3 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":30217,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-30200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Research Briefing - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Research Briefing - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-14T04:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-14T00:31:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"Prescient Therapeutics Research Briefing\",\"datePublished\":\"2024-03-14T04:23:00+00:00\",\"dateModified\":\"2025-01-14T00:31:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\"},\"wordCount\":248,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\",\"name\":\"Prescient Therapeutics Research Briefing - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\",\"datePublished\":\"2024-03-14T04:23:00+00:00\",\"dateModified\":\"2025-01-14T00:31:28+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Research Briefing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Research Briefing - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Research Briefing - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/","og_site_name":"PTX Therapeutics","article_published_time":"2024-03-14T04:23:00+00:00","article_modified_time":"2025-01-14T00:31:28+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png","type":"image\/png"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"Prescient Therapeutics Research Briefing","datePublished":"2024-03-14T04:23:00+00:00","dateModified":"2025-01-14T00:31:28+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/"},"wordCount":248,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/","name":"Prescient Therapeutics Research Briefing - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png","datePublished":"2024-03-14T04:23:00+00:00","dateModified":"2025-01-14T00:31:28+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2024\/03\/PTX-pitt-street-WC-Thumbnail-RM-page-1.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-research-briefing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Research Briefing"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30200"}],"version-history":[{"count":6,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30200\/revisions"}],"predecessor-version":[{"id":30225,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30200\/revisions\/30225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30217"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}